Cardiac output-guided haemodynamic therapy for patients undergoing major gastrointestinal surgery: OPTIMISE II randomised clinical trial
BMJ · 03.12.2024 · e080439
DOI: 10.1136/bmj-2024-080439 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BMJ, online erschienen am 03.12.2024. Verfasst von OPTIMISE II Trial Group. Hauptthemen laut MEDLINE: Cardiac Output, Fluid Therapy, Digestive System Surgical Procedures, Postoperative Complications. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UK National Institute for Health and Care Research (NIHR), National Institute for Health and Care Research.
Abstract (Originalsprache)
Objectives
To evaluate the clinical effectiveness and safety of a perioperative algorithm for cardiac output-guided haemodynamic therapy in patients undergoing major gastrointestinal surgery.
Design
Multicentre randomised controlled trial.
Setting
Surgical services of 55 hospitals worldwide.
Participants
2498 adults aged ≥65 years with an American Society of Anesthesiologists physical status classification of II or greater and undergoing major elective gastrointestinal surgery, recruited between January 2017 and September 2022.
Interventions
Participants were assigned to minimally invasive cardiac output-guided intravenous fluid therapy with low dose inotrope infusion during and four hours after surgery, or to usual care without cardiac output monitoring. Main outcome measures The primary outcome was postoperative infection within 30 days of randomisation. Safety outcomes were acute cardiac events within 24 hours and 30 days. Secondary outcomes were acute kidney injury within 30 days and mortality within 180 days.
Results
In 2498 patients (mean age 74 (standard deviation 6) years, 57% women), the primary outcome occurred in 289/1247 (23.2%) intervention patients and 283/1247 (22.7%) usual care patients (adjusted odds ratio 1.03 (95% confidence interval 0.84 to 1.25); P=0.81). Acute cardiac events within 24 hours occurred in 38/1250 (3.0%) intervention patients and 21/1247 (1.7%) usual care patients (adjusted odds ratio 1.82 (1.06 to 3.13); P=0.03). This difference was primarily due to an increased incidence of arrhythmias among intervention patients. Acute cardiac events within 30 days occurred in 85/1249 (6.8%) intervention patients and 79/1247 (6.3%) usual care patients (adjusted odds ratio 1.06 (0.77 to 1.47); P=0.71). Other secondary outcomes did not differ.
Conclusions
This clinical effectiveness trial in patients undergoing major elective gastrointestinal surgery did not provide evidence that cardiac output-guided intravenous fluid therapy with low dose inotrope infusion could reduce the incidence of postoperative infections. The intervention was associated with an increased incidence of acute cardiac events within 24 hours, in particular tachyarrhythmias. Based on these findings, the routine use of this treatment approach in unselected patients is not recommended.
Trial registration
ISRCTN Registry NCT39653756 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Förderung
- UK National Institute for Health and Care Research (NIHR)
- National Institute for Health and Care Research
Zitieren
APA
OPTIMISE II Trial Group (2024). Cardiac output-guided haemodynamic therapy for patients undergoing major gastrointestinal surgery: OPTIMISE II randomised clinical trial. BMJ, e080439. https://doi.org/10.1136/bmj-2024-080439
Vancouver
OPTIMISE II Trial Group. Cardiac output-guided haemodynamic therapy for patients undergoing major gastrointestinal surgery: OPTIMISE II randomised clinical trial. BMJ. 2024:e080439. doi:10.1136/bmj-2024-080439
BibTeX
@article{OPTIMISEIITrialGroup2024,
author = {OPTIMISE II Trial Group, OPTIMISE II Trial Group},
title = {Cardiac output-guided haemodynamic therapy for patients undergoing major gastrointestinal surgery: OPTIMISE II randomised clinical trial},
journal = {BMJ},
year = {2024},
pages = {e080439},
doi = {10.1136/bmj-2024-080439}
}
EUVIMED